These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 639173)

  • 21. Changes in glycosylation of L1210 cells after exposure to various antimetabolites.
    De Graaf TW; Slot SS; Peters GJ; Van Dijk W
    Eur J Cancer; 1993; 29A(12):1760-5. PubMed ID: 8398306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of 5-fluorouridine 5'-phosphate by a pyrimidine phosphoribosyltransferase of mammalian origin. II. Correlation between the tumor levels of the enzyme and the 5-fluorouracil-promoted increase in survival of tumor-bearing mice.
    Reyes P; Hall TC
    Biochem Pharmacol; 1969 Oct; 18(10):2587-90. PubMed ID: 4327386
    [No Abstract]   [Full Text] [Related]  

  • 23. Role of deoxycytidine kinase in the inhibitory activity of 5-substituted 2'-deoxycytidines and cytosine arabinosides on tumor cell growth.
    Balzarini J; De Clercq E
    Mol Pharmacol; 1983 Jan; 23(1):175-81. PubMed ID: 6306422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells.
    Lauzon GJ; Paterson AR; Belch AW
    Cancer Res; 1978 Jun; 38(6):1730-3. PubMed ID: 274175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimetabolites.
    Johnston PG; Takimoto CH; Grem JL; Fidias P; Grossbard ML; Chabner BA; Allegra CJ; Chu E
    Cancer Chemother Biol Response Modif; 1997; 17():1-39. PubMed ID: 9551206
    [No Abstract]   [Full Text] [Related]  

  • 26. 5-fluorouracil and 5-fluoro-2'-deoxyuridine follow different metabolic pathways in the induction of cell lethality in L1210 leukaemia.
    Roobol C; De Dobbeleer GB; Bernheim JL
    Br J Cancer; 1984 Jun; 49(6):739-44. PubMed ID: 6234011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimetabolites.
    Chu E; Johnston PG; Grem JL; Takimoto CH; Van Groeningen C; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1994; 15():1-31. PubMed ID: 7779582
    [No Abstract]   [Full Text] [Related]  

  • 28. Flavonoids potentiate the efficacy of cytarabine through modulation of drug-induced apoptosis.
    Nadova S; Miadokova E; Cipak L
    Neoplasma; 2007; 54(3):202-6. PubMed ID: 17447850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimetabolites.
    Allegra CJ; Baram J; Chabner BA; Yeh GC; Aiba K; Curt GA
    Cancer Chemother Biol Response Modif; 1987; 9():1-22. PubMed ID: 2484324
    [No Abstract]   [Full Text] [Related]  

  • 30. The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia.
    Chadwick M; Rogers WI
    Cancer Res; 1972 May; 32(5):1045-56. PubMed ID: 4259631
    [No Abstract]   [Full Text] [Related]  

  • 31. Antimetabolites.
    Chu E; Grem JL; Johnston PG; Politi PM; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1992; 13():1-30. PubMed ID: 1389906
    [No Abstract]   [Full Text] [Related]  

  • 32. Biochemical and genetic studies of a mutant strain of mouse leukemia L1210 resistant to 1-beta-D-arabinofuranosylcytosine (Cytarabine).
    Bach MK
    Cancer Res; 1969 May; 29(5):1036-44. PubMed ID: 5781095
    [No Abstract]   [Full Text] [Related]  

  • 33. Antimetabolites.
    Chu E; Johnston PG; Takimoto CH; Politi PM; Grem JL; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1993; 14():1-25. PubMed ID: 8312100
    [No Abstract]   [Full Text] [Related]  

  • 34. Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells.
    Skipper HE; Schabel FM; Wilcox WS
    Cancer Chemother Rep; 1967 Jun; 51(3):125-65. PubMed ID: 6043735
    [No Abstract]   [Full Text] [Related]  

  • 35. Camptothecin effects on DNA synthesis in murine leukemia cells.
    Kessel D; Bosmann HB; Lohr K
    Biochim Biophys Acta; 1972 May; 269(2):210-6. PubMed ID: 5063907
    [No Abstract]   [Full Text] [Related]  

  • 36. Combination chemotherapy: the interaction of methotrexate and 5-fluorouracil.
    Tattersall MH; Jackson RC; Connors TA; Harrap KR
    Eur J Cancer (1965); 1973 Oct; 9(10):733-9. PubMed ID: 4529730
    [No Abstract]   [Full Text] [Related]  

  • 37. Accumulation of two alkylating agents, nitrogen mustard and busulfan, by murine leukemia cells in vitro.
    Kessel D; Myers M; Wodinsky I
    Biochem Pharmacol; 1969 May; 18(5):1229-34. PubMed ID: 5815278
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical pharmacology of anticancer agents (Part 4). Antimetabolites (1)].
    Nakamura T; Uchida M; Ueda T
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):265-76. PubMed ID: 1736842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the LRP (lung resistance-related protein) gene by short-term exposure of human leukemia cells to phorbol ester and cytarabine.
    Komarov PG; Shtil AA; Holian O; Tee L; Buckingham L; Mechetner EB; Roninson IB; Coon JS
    Oncol Res; 1998; 10(4):185-92. PubMed ID: 9778689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
    Moyer JD; Smith PA; Levy EJ; Handschumacher RE
    Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.